Clinical research Center of Alabama

Birmingham, Alabama 35249

1 studies enrolling now · 30 studies all time

What they study most

Angioedema, Asthma, Asthma in Children, Atopic Dermatitis, Chronic Idiopathic Urticaria, Chronic Inducible Urticaria, Chronic Spontaneous Urticaria, Dermatitis, Atopic, Eczema, Hereditary Angioedema, Hereditary Angioedema (HAE), Hives

Studies at this site

• A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis — Enrolling by invitation
• A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis — Running, not enrolling
• A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis — Running, not enrolling
• Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks — Completed
• Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria — Completed
• A Study of CDX-0159 in Patients With Chronic Inducible Urticaria — Completed
• Study to Evaluate Tezepelumab in Adults With Chronic Spontaneous Urticaria — Completed
• A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3) — Completed
• Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1) — Completed
• Treatment of Hereditary Angioedema Prodrome with Recombinant C1-esterase Inhibitor (Ruconest) — Completed
• A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor — Completed
• A Study to Evaluate Safety and Effectiveness of Cendakimab (CC-93538) in Participants With Moderate to Severe Atopic Dermatitis — Completed
• A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) — Completed
• A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary Immunodeficiency — Completed
• A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria — Completed
• CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks — Completed
• (PROSPECTOR) Screening Study Evaluating the Prevalence of the KIT D816V Mutation in Patients With Systemic Mast Cell Activation — Completed
• A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II in North America — Completed
• Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy — Completed
• Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients — Completed
• AR101 Real-World Open-Label Extension Study — Completed
• Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children (RAMSES) — Completed
• Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE — Completed
• Study of Equivalence of Generic Pimecrolimus Cream 1% and Elidel® 1% in Subjects With Mild to Moderate Atopic Dermatitis — Completed
• Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID) — Completed
• An Evaluation Of PF-03715455 In Moderate To Severe Uncontrolled Asthma — Stopped early
• Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis — Completed
• Safety, Pharmacokinetics and Preliminary Efficacy of Asimadoline in Pruritus Associated With Atopic Dermatitis — Completed
• Formula for Children With Cow's Milk Allergy — Completed
• TC-6987 for the Treatment of Mild to Moderate Asthma — Completed